Results
1 -
10 of
87Cincinelli Raffaella, Musso Loana, Merlini Lucio, Giannini Giuseppe, Vesci Loredana, Milazzo Ferdinando M., Carenini Nives, Perego Paola, Penco Sergio, Artali Roberto, Zunino Franco, Pisano Claudio, Dallavalle Sabrina.
7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors, Bioorganic & Medicinal Chemistry, 2014 Elliott Richard J. R., Jarvis Ashley, Rajasekaran Mohan B., Menon Malini, Bowers Leandra, Boffey Ray, Bayford Melanie, Firth-Clark Stuart, Key Rebekah, Aqil Rehan, Kirton Stewart B., Niculescu-Duvaz Dan, Fish Laura, Lopes Filipa, McLeary Robert, Trindade Ines, Vendrell Elisenda, Munkonge Felix, Porter Rod, Perrior Trevor, Springer Caroline, Oliver Antony W., Pearl Laurence H., Ashworth Alan, Lord Christopher J..
Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors, MedChemComm, 2015 Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies, Clinical Pharmacokinetics PARP Inhibitors, Current Breast Cancer Reports Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies, Clinical Pharmacokinetics Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP, Journal of Hematology & Oncology Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?, Clinical and Translational Oncology ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells, Journal of Translational Medicine PARP, Cancer Therapeutic Targets Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma, Journal of Translational Medicine